Skip to main content
S&P 5007,568.92+0.36%DOW51,786.72-0.38%NASDAQ25,372.01+0.83%BTC$76,850.00-0.36%ETH$2,261.28+0.13%GOLD$3,968.20+0.71%OIL$95.60-0.51%
Smart Investors Daily
SID Premium
Boundless Bio, Inc. logo

NASDAQ · BOLD

Boundless Bio, Inc.

Healthcare · Biotechnology

$2.38

Down-$0.06 (-2.46%)

Updated Nov 4, 2026, 2:19 AM

SID Score

4.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
25.74M
P/E ratio
-0.4
Dividend yield
0.00%
52-week range
$1.07 – $3.16
Volume
56.08K
Avg. volume
159.75K

Price performance · BOLD

BOLD price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

BOLD closed at $2.38 after 21 trading sessions, down 7.39% for the selected period.

Last close
$2.38
Period change
-7.39%
Period low
$2.31
Period high
$2.64
Daily close
View OHLC price history
BOLD OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$2.44$2.548$2.38$2.3856.08K
Nov 2, 2026$2.48$2.50$2.40$2.4491.16K
Oct 30, 2026$2.525$2.59$2.43$2.4747.01K
Oct 29, 2026$2.51$2.5425$2.4525$2.4857.51K
Oct 28, 2026$2.41$2.60$2.41$2.50246.01K
Oct 27, 2026$2.41$2.43$2.38$2.4191.09K
Oct 26, 2026$2.40$2.4342$2.36$2.4159.1K
Oct 23, 2026$2.41$2.44$2.345$2.3634.87K
Oct 22, 2026$2.45$2.46$2.38$2.44114.06K
Oct 21, 2026$2.53$2.565$2.41$2.4464.26K
Oct 20, 2026$2.33$2.49$2.33$2.4389.74K
Oct 19, 2026$2.38$2.485$2.31$2.31219.72K
Oct 16, 2026$2.37$2.49$2.28$2.34711.18K
Oct 15, 2026$2.40$2.525$2.335$2.35181.98K
Oct 14, 2026$2.43$2.49$2.385$2.39129.82K
Oct 13, 2026$2.55$2.69$2.39$2.43463.16K
Oct 12, 2026$2.53$2.59$2.50$2.5560.47K
Oct 9, 2026$2.58$2.64$2.47$2.53166.79K
Oct 8, 2026$2.58$2.67$2.50$2.58334.16K
Oct 7, 2026$2.58$2.71$2.562$2.64116.89K
Oct 6, 2026$2.62$2.65$2.515$2.5765.18K

Latest BOLD news

The latest Smart Investors Daily articles mentioning BOLD.

Stock researchCompany · Overview

BOLD research

Overview

Company profile and research snapshot.

Company profile

Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$3.06
Implied upside
—
Analysts
—
BOLD recent ratings
DateFirmRatingTarget
Aug 11, 2025HC Wainwright & Co.Buy—
Jun 2, 2025HC Wainwright & Co.Buy—
May 28, 2025Leerink PartnersMarket Perform—
Dec 13, 2024GuggenheimNeutral—
Apr 22, 2024Leerink PartnersOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 28, 2026

Callio Therapeutics Appoints Chris Hassig, PhD, as Chief Scientific Officer

Industry veteran brings more than two decades of oncology drug discovery leadership to advance Callio's dual-payload ADC pipelineSAN DIEGO and SEATTLE and SINGAPORE, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Callio Therapeutics (“Callio” or “the Company”), a global, clinical-stage biotechnology company advancing dual-payload antibody-drug conjugates (ADCs) as the next frontier of rationally designed targeted cancer therapy, today announced the appointment of Chris Hassig, PhD, as Chief Scientific Offic

Yahoo · Sep 9, 2026

Callio Therapeutics Appoints Zachary Hornby as Chief Executive Officer

Veteran biotech executive to lead company growth as it advances multiple dual-payload ADCs through clinical development for people living with cancer Piers Ingram, PhD, Co-Founder, transitions to Senior Advisor and continues to serve on the Board of Directors; Jerome Boyd-Kirkup, PhD, founding Chief Scientific Officer, transitions to Senior Scientific Advisor SAN DIEGO and SEATTLE and SINGAPORE, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Callio Therapeutics (“Callio” or “the Company”), a clinical-stage

Benzinga · Sep 9, 2026

Callio Therapeutics Appoints Zachary Hornby As CEO

Veteran biotech executive to lead company growth as it advances multiple dual-payload ADCs through clinical development for people living with cancerPiers Ingram, PhD, Co-Founder, transitions to Senior Advisor and

Benzinga · Aug 10, 2026

Boundless Bio Q2 EPS $(1.06) Misses $(0.61) Estimate

Boundless Bio (NASDAQ:BOLD) reported quarterly losses of $(1.06) per share which missed the analyst consensus estimate of $(0.61) by 73.77 percent. This is a 51.43 percent decrease over losses of $(0.70) per share from

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By